CAPR Investor Losses: Capricor Therapeutics Clinical Data Announcement and Corresponding 64% Stock Drop Trigger Securities Class Action for Investors
Capricor Therapeutics faces a securities-fraud class action alleging misstatements about Deramiocel and the clinical data supporting its Biologics License Application after the stock fell 64%. The filing puts regulatory-data credibility and litigation exposure at the center of the company’s next catalyst.
PR NEWSWIRE / FILEThe story
The lawsuit, announced by a securities law firm on Aug. 25, alleges that Capricor misrepresented Deramiocel and the integrity of clinical data underpinning its Biologics License Application. The allegations follow a 64% decline in Capricor's stock.
The named issues connect the company's valuation to both Deramiocel's clinical evidence and the regulatory submission built on that evidence. The litigation also creates a second channel of scrutiny beyond the underlying drug program.
Next, the docket, Capricor's response, and any regulatory developments will determine whether the allegations broaden the existing uncertainty around the application.
Our read · Tue, Aug 25
The securities-fraud filing moves the risk to the downside for CAPR by pairing Deramiocel data scrutiny with fresh litigation exposure.
Why. The immediate consequence is a higher uncertainty premium around both the Deramiocel application and the credibility of the supporting clinical data. The 64% stock drop is already part of the record, so without a dated forward catalyst or enrichment on valuation, positioning, and the lawsuit’s merits, the evidence supports a downside risk read but not a quantified new trade.
Both cases
What could change this view: A company response, court dismissal, or regulatory confirmation that the application and clinical data remain intact would undercut the litigation-driven downside case.
Who reported it · 1
Keep reading
More on CAPR
Capricor reports 76% slower upper-limb decline after deramiocel switchLatest on the Wire
AMD shares fall 11% after Hunterbrook warns over China linksWalmart raises full-year outlook as e-commerce wins shoppersAnthropic IPO could become the largest in US history on ThursdayContinuing claims rise as Goldman sees Fed hikes in December and MarchPIF Tower in Riyadh reportedly damaged in second Houthi attackContinue on the Wire →Latest on the Wire
PIF Tower in Riyadh reportedly damaged in second Houthi attackTrump Media buys back $100 million of notes ahead of Nov. 30 cash demandBiohaven reports confirmed BHV-1530 responses in two FGFR3 cancersTrump, Xi and Putin pledge more refined fuel after first trilateral summitContinue on the Wire →Top this week
Nvidia allies lobby board to bring back Jensen Huang as CEONvidia chair rules out Huang return as CEO after 75% sales outlookAnthropic Said to Guide IPO Pricing Above Market RangeNvidia interim CEO Colette Kress faces first earnings test after HuangNvidia CEO Jensen Huang reportedly resigns as US-China tensions riseAbout this report
Reported by PR Newswire, . Who answers for this
The only report in this record. Closes are licensed end-of-day data from Databento; the move after a story is its first close against the close before it. How this is decided →
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →